ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · IEX Real-Time Price · USD
0.735
+0.015 (2.14%)
At close: Jul 26, 2024, 3:58 PM
0.731
-0.004 (-0.60%)
After-hours: Jul 26, 2024, 6:41 PM EDT
ABVC BioPharma Revenue
ABVC BioPharma had revenue of $1.21K in the quarter ending March 31, 2024, a decrease of -99.06%. This brings the company's revenue in the last twelve months to $25.36K, down -97.63% year-over-year. In the year 2023, ABVC BioPharma had annual revenue of $152.43K, down -84.28%.
Revenue (ttm)
$25.36K
Revenue Growth
-97.63%
P/S Ratio
355.86
Revenue / Employee
$1,335
Employees
19
Market Cap
9.03M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 152.43K | -817.35K | -84.28% |
| Dec 31, 2022 | 969.78K | 613.99K | 172.57% |
| Dec 31, 2021 | 355.80K | -127.25K | -26.34% |
| Dec 31, 2020 | 483.05K | -218.67K | -31.16% |
| Dec 31, 2019 | 701.72K | 694.76K | 9,987.97% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Molecular Templates | 31.76M |
| Vivos Therapeutics | 13.36M |
| Syra Health | 6.08M |
| Kineta | 5.16M |
| Elevai Labs | 2.18M |
| Nexalin Technology | 158.86K |
| Organovo Holdings | 109.00K |
| Silo Pharma | 72.10K |
ABVC News
- 3 months ago - AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - GlobeNewsWire
- 3 months ago - ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - GlobeNewsWire
- 3 months ago - ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - GlobeNewsWire
- 4 months ago - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - GlobeNewsWire
- 4 months ago - ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine - GlobeNewsWire
- 4 months ago - ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update - GlobeNewsWire
- 5 months ago - ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues - GlobeNewsWire
- 5 months ago - ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) - GlobeNewsWire